# Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis

Study · id `cardio:ct-nct05540587` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05540587](<https://clinicaltrials.gov/study/NCT05540587>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05540587

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems; Valve and congenital heart disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

## Technical summary

Registry record NCT05540587. Randomized; no masking; primary purpose treatment. Start 2022-05-20 (actual); primary completion 2024-05-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT05540587, source copy `cardio:ctgov-nct05540587-2022-09-14`, retrieved 2026-10-26)
- Started: 2022-05-20 (actual) (ClinicalTrials.gov record NCT05540587, source copy `cardio:ctgov-nct05540587-2022-09-14`, retrieved 2026-10-26)
- Primary completion: 2024-05-20 (anticipated) (ClinicalTrials.gov record NCT05540587, source copy `cardio:ctgov-nct05540587-2022-09-14`, retrieved 2026-10-26)
- Completion: 2026-05-20 (anticipated) (ClinicalTrials.gov record NCT05540587, source copy `cardio:ctgov-nct05540587-2022-09-14`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05540587, source copy `cardio:ctgov-nct05540587-2022-09-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05540587-2022-09-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis
- Acronym: ERTEMIS
- Condition: Mitral Valve Stenosis
- Condition: Atrial Fibrillation
- Condition: Stroke
- Condition: Systemic Embolism
- Intervention (Drug): Edoxaban
- Intervention (Drug): Warfarin
- Lead sponsor: Sung-Hwan Kim
- Lead sponsor class: OTHER
- Collaborator: Daiichi Sankyo Korea Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral stenosis (`cardio:mitral-stenosis`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Edoxaban (`cardio:edoxaban`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)

## Provenance

Content hash: c5398ef40b2d9205ea0c07753b083fce4fc9ff4c5ecd93454899d34dbf2fdb67
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
